Chemcon Speciality Chemicals Ltd
Incorporated in 1988, Chemcon Speciality Chemicals Ltd manufactures Pharmaceutical intermediates and Oilfield Chemicals[1]
- Market Cap ₹ 512 Cr.
- Current Price ₹ 140
- High / Low ₹ 295 / 125
- Stock P/E 24.2
- Book Value ₹ 140
- Dividend Yield 0.00 %
- ROCE 7.01 %
- ROE 5.00 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 1.00 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -4.57% over past five years.
- Company has a low return on equity of 7.05% over last 3 years.
- Earnings include an other income of Rs.14.5 Cr.
- Dividend payout has been low at 8.86% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of BSE Allcap BSE Commodities
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53 | 63 | 97 | 88 | 158 | 303 | 262 | 243 | 257 | 303 | 267 | 207 | 219 | |
| 46 | 56 | 87 | 79 | 112 | 237 | 192 | 162 | 175 | 232 | 240 | 174 | 192 | |
| Operating Profit | 6 | 8 | 10 | 9 | 46 | 66 | 70 | 81 | 82 | 71 | 27 | 33 | 27 |
| OPM % | 12% | 12% | 10% | 10% | 29% | 22% | 27% | 33% | 32% | 23% | 10% | 16% | 12% |
| 0 | -1 | 0 | 0 | 0 | 2 | 4 | 5 | 9 | 13 | 13 | 14 | 14 | |
| Interest | 2 | 2 | 3 | 2 | 3 | 4 | 5 | 4 | 1 | 1 | 4 | 3 | 2 |
| Depreciation | 1 | 2 | 2 | 2 | 2 | 3 | 5 | 6 | 6 | 8 | 10 | 11 | 11 |
| Profit before tax | 3 | 3 | 5 | 5 | 41 | 61 | 65 | 76 | 84 | 74 | 26 | 33 | 29 |
| Tax % | 60% | 3% | 35% | 37% | 35% | 30% | 25% | 26% | 25% | 26% | 27% | 26% | |
| 1 | 3 | 3 | 3 | 26 | 43 | 49 | 56 | 63 | 55 | 19 | 24 | 21 | |
| EPS in Rs | 1.46 | 3.35 | 4.09 | 3.78 | 33.21 | 13.54 | 15.37 | 15.40 | 17.13 | 15.04 | 5.24 | 6.67 | 5.78 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 27% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | -5% |
| 3 Years: | -7% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | -13% |
| 3 Years: | -27% |
| TTM: | -10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -19% |
| 3 Years: | -15% |
| 1 Year: | -19% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 11% |
| 3 Years: | 7% |
| Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 32 | 32 | 37 | 37 | 37 | 37 | 37 | 37 |
| Reserves | 11 | 13 | 16 | 19 | 46 | 65 | 115 | 317 | 381 | 421 | 440 | 464 | 476 |
| 14 | 12 | 13 | 20 | 17 | 33 | 46 | 6 | 36 | 64 | 43 | 25 | 0 | |
| 12 | 10 | 9 | 15 | 27 | 43 | 34 | 44 | 45 | 32 | 26 | 29 | 35 | |
| Total Liabilities | 45 | 44 | 46 | 63 | 97 | 173 | 226 | 404 | 498 | 553 | 545 | 554 | 548 |
| 20 | 20 | 19 | 24 | 30 | 40 | 49 | 67 | 82 | 141 | 146 | 149 | 144 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 9 | 34 | 14 | 42 | 40 | 47 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 11 |
| 25 | 24 | 27 | 38 | 67 | 133 | 173 | 328 | 382 | 398 | 356 | 355 | 346 | |
| Total Assets | 45 | 44 | 46 | 63 | 97 | 173 | 226 | 404 | 498 | 553 | 545 | 554 | 548 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 | 5 | 10 | 14 | 11 | 12 | 65 | 74 | 13 | 12 | 41 | ||
| -5 | -2 | -9 | -7 | -24 | -16 | -152 | -92 | -16 | -25 | -19 | ||
| -3 | -3 | -2 | -6 | 12 | 4 | 111 | 30 | 12 | -25 | -22 | ||
| Net Cash Flow | -1 | -0 | -1 | 1 | -0 | 0 | 23 | 11 | 9 | -37 | 0 | |
| Free Cash Flow | 3 | 3 | 2 | 7 | -2 | -2 | 34 | 24 | -32 | -31 | 31 | |
| CFO/OP | 105% | 65% | 130% | 62% | 51% | 41% | 99% | 119% | 49% | 78% | 131% |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 40 | 52 | 51 | 93 | 68 | 77 | 124 | 142 | 146 | 81 | 112 | 91 |
| Inventory Days | 146 | 74 | 45 | 58 | 99 | 91 | 118 | 175 | 102 | 164 | 119 | 261 |
| Days Payable | 97 | 79 | 39 | 81 | 82 | 57 | 63 | 67 | 70 | 44 | 23 | 49 |
| Cash Conversion Cycle | 89 | 47 | 57 | 70 | 86 | 111 | 179 | 250 | 177 | 201 | 208 | 303 |
| Working Capital Days | 85 | 64 | 59 | 8 | 61 | 59 | 135 | 184 | 105 | 108 | 162 | 211 |
| ROCE % | 17% | 17% | 22% | 16% | 74% | 65% | 43% | 29% | 21% | 15% | 6% | 7% |
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Installed Capacity - Inorganic Chemicals (Bromides) MTPA |
|
|||||||
| Manufacturing Units Count |
||||||||
| Production / Sales Volume - Total MT |
||||||||
| Sales Volume - Inorganic Chemicals (Bromides) MT |
||||||||
| Sales Volume - Organic Chemicals (HMDS, CMIC, Bromobenzene, 2-Bromo) MT |
||||||||
| Installed Capacity - Organic Chemicals MTPA |
||||||||
| Capacity Utilization - HMDS % |
||||||||
| Global Product Ranking - HMDS Rank |
||||||||
Documents
Announcements
- Closure of Trading Window 25 Mar
- Announcement under Regulation 30 (LODR)-Investor Presentation 13 Feb
- Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Feb
- The Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2025. 12 Feb
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday, 12Th February, 2026
12 Feb - Approved Q3/9M FY26 unaudited results; slump sale acquisition of Shivam Petrochem for Rs36.00 crore.
Annual reports
Concalls
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
-
Oct 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptAI SummaryPPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Dec 2020Transcript PPT
Business Overview:[1]
CSCL is an ISO 9001:2015 and ISO 14001:2015 certified manufacturer of silanes, pharma intermediates, agro intermediates, and oil field chemicals. It is the largest manufacturer of specialised chemicals like HMDS and CMIC, predominantly used in the pharmaceutical industry.